



AstraZeneca Pharma India Limited

Regd. Office : 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 30 SEPTEMBER 2010

Rs in lakhs (except for number of shares)						
SI No.	Particulars	3 months ended 30.09.2010 (Unaudited)	3 months ended 30.09.2009 (Unaudited)	9 months ended 30.09.2010 (Unaudited)	9 months ended 30.09.2009 (Unaudited)	Previous accounting year ended 31.12.2009 (Audited)
1	(a) Net sales (net of excise duty)	12,436.68	9,737.48	32,260.69	27,067.23	38,552.12
	(b) Other operating income:					
	- Service income	163.87	356.49	1,221.84	972.13	1,111.21
2	Expenditure					
	(a) (Increase) / decrease in stock-in-trade and work-in-progress	418.56	174.31	(421.01)	80.47	12.76
	(b) Consumption of raw materials and packing materials	1,526.58	1,489.21	4,361.33	3,244.06	4,575.41
	(c) Purchase of traded goods	1,965.99	1,485.53	6,087.17	5,288.13	7,507.77
	(d) Employees cost	2,965.36	2,209.60	8,677.96	6,454.35	8,282.94
	(e) Depreciation	186.88	153.21	520.28	451.29	607.67
	(f) Other expenditure	3,024.62	2,764.66	10,396.73	7,478.08	10,398.26
	(g) Total	10,087.99	8,276.52	29,622.46	22,996.38	31,384.81
3	Profit from operations before other income, interest & exceptional items (1-2)	2,512.56	1,817.45	3,860.07	5,042.98	8,278.52
4	Other income	89.71	69.54	255.03	458.04	574.40
5	Profit before interest & exceptional items (3+4)	2,602.27	1,886.99	4,115.10	5,501.02	8,852.92
6	Interest	-	-	-	13.70	13.70
7	Profit after interest but before exceptional items (5-6)	2,602.27	1,886.99	4,115.10	5,487.32	8,839.22
8	Exceptional items	-	-	-	-	-
9	Profit from ordinary activities before tax (7+8)	2,602.27	1,886.99	4,115.10	5,487.32	8,839.22
10	Tax expense	849.70	589.75	1,369.68	1,934.20	3,077.49
11	Net profit from ordinary activities after tax (9-10)	1,752.57	1,297.24	2,745.42	3,553.12	5,761.73
12	Extraordinary Item	-	-	-	-	-
13	Net profit for the period (11-12)	1,752.57	1,297.24	2,745.42	3,553.12	5,761.73
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00	500.00
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year					13,951.82
16	Basic and diluted earnings (Rs) per share (not annualised)	7.01	5.19	10.98	14.21	23.05
17	Public shareholding					
	- Number of shares	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%
18	Promoters and promoter group shareholding					
	a) Pledged / Encumbered					
	- Number of shares	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-
	b) Non-encumbered					
	- Number of shares	22,499,950	22,499,950	22,499,950	22,499,950	22,499,950
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	89.9998%	89.9998%	89.9998%	89.9998%	89.9998%

Notes :

1. The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 27 October 2010.
2. Status of investor complaints : a) Pending as on 1 July 2010 - NIL b) Received during the quarter - 8 c) Disposed off during the quarter - 8 d) Pending as on 30 September 2010 - NIL.
3. The board of directors at their meeting held on 23 February 2010 have approved the change in the Company's statutory accounting year from "January-December" to "April-March". Accordingly, the financial accounts and annual report for the year ending 31 March 2011 shall be for a period of 15 months, i.e. from 1 January 2010 to 31 March 2011.
4. The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. Others comprise service income pertaining to clinical trials and co-promotion activities.
5. Previous period figures have been regrouped / reclassified, wherever necessary to conform to the current period's presentation.

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED

Rs in lakhs						
SI No.	Particulars	3 months ended 30.09.2010 (Unaudited)	Corresponding 3 months ended in the previous year 30.09.2009 (Unaudited)	9 months ended 30.09.2010 (Unaudited)	Corresponding 9 months ended in the previous year 30.09.2009 (Unaudited)	Previous Accounting year ended 31.12.2009 (Audited)
1	Segment Revenue					
	(a) Healthcare	12,442.65	9,751.97	32,277.27	27,094.76	38,583.38
	(b) Others	163.87	356.49	1,221.84	972.13	1,111.21
	Total	12,606.52	10,108.46	33,499.11	28,066.89	39,694.59
	Less: Inter-segment Revenue	-	-	-	-	-
	Net Income From Operations	12,606.52	10,108.46	33,499.11	28,066.89	39,694.59
2	Segment Results					
	Profit before Tax and interest					
	(a) Healthcare	2,419.95	1,823.58	3,769.48	5,052.73	8,286.13
	(b) Others	98.58	8.36	107.17	17.78	23.65
	Total	2,518.53	1,831.94	3,876.65	5,070.51	8,309.78
	Add: Other Income	83.74	55.05	238.45	430.51	543.14
	Less: Interest	-	-	-	13.70	13.70
	Total Profit Before Tax	2,602.27	1,886.99	4,115.10	5,487.32	8,839.22
3	Capital Employed					
	(a) Healthcare	8,685.63	9,413.01	8,685.63	9,413.01	11,595.38
	(b) Others	280.73	(481.82)	280.73	(481.82)	(378.11)
	(c) Unallocated	8,240.55	6,236.91	8,240.55	6,236.91	3,234.55
	Total	17,206.91	15,168.10	17,206.91	15,168.10	14,451.82

Note: Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.

By Order of the Board of Directors
For ASTRAZENECA PHARMA INDIA LIMITED

Place: Mumbai
Dated: 27 October 2010

Anandh Balasundaram
Managing Director

33cm(h) x 16cm(w)